Prostate
Cancer OS and rPFS benefits
in chemo-naive mCRPC
Alan So, MD, FRCPC,
Associate Professor, Department of Urologic
Sciences, University of British Columbia;
Research Scientist, Prostate Center, Vancouver
General Hospital.
To view the complete article click
here (pdf format)
TRIAL SUMMARY:
Confirmed benefit of abiraterone in progressive
mCRPC pre docetaxel.
To view the complete article click
here (pdf format)
Reports of recent clinical trial data from ASCO 2012
In Brief
Already
known
Abiraterone
has established survival benefit in patients
with mCRPC who have been treated with docetaxel.
What this
study showed
COU-AA-302
is the first randomized trial to demonstrate
both OS and rPFS benefits in chemo-naive mCRPC
and to show that inhibition of persistent
extragonadal androgen synthesis significantly
delays initiation of cytotoxic CT.
Median OS
was not reached in the abiraterone arm; the
median OS in the placebo arm (27.2 months)
is the longest measured in any Phase III mCRPC
study.
Next steps
Studies to
determine the OS benefit of abiraterone in
patients with progressive mCRPC not yet treated
with docetaxel.
